Differentially expressed microRNAs in experimental cerebral malaria and their involvement in endocytosis, adherens junctions, FoxO and TGF-β signalling pathways by Martin-Alonso, Aarón et al.
1SCIENTIFIC RepoRts |  (2018) 8:11277  | DOI:10.1038/s41598-018-29721-y
www.nature.com/scientificreports
Differentially expressed microRNAs 
in experimental cerebral malaria 
and their involvement in 
endocytosis, adherens junctions, 
FoxO and TGF-β signalling 
pathways
Aarón Martin-Alonso1, Amy Cohen2, María Antonieta Quispe-Ricalde3, Pilar Foronda1, 
Agustín Benito4,5, Pedro Berzosa4,5, Basilio Valladares1 & Georges E. Grau2
Cerebral malaria (CM) is the most severe manifestation of infection with Plasmodium, however its 
pathogenesis is still not completely understood. microRNA (miRNA) have been an area of focus in 
infectious disease research, due to their ability to affect normal biological processes, and have been 
shown to play roles in various viral, bacterial and parasitic infections, including malaria. The expression 
of miRNA was studied following infection of CBA mice with either Plasmodium berghei ANKA (causing 
CM), or Plasmodium yoelii (causing severe but non-cerebral malaria (NCM)). Using microarray analysis, 
miRNA expression was compared in the brains of non-infected (NI), NCM and CM mice. Six miRNA were 
significantly dysregulated between NCM and CM mice, and four of these, miR-19a-3p, miR-19b-3p, miR-
142-3p and miR-223-3p, were further validated by qPCR assays. These miRNA are significantly involved 
in several pathways relevant to CM, including the TGF-β and endocytosis pathways. Dysregulation of 
these miRNA during CM specifically compared with NCM suggests that these miRNA, through their 
regulation of downstream targets, may be vitally involved in the neurological syndrome. Our data 
implies that, at least in the mouse model, miRNA may play a regulatory role in CM pathogenesis.
Malaria is a serious and sometimes life-threatening disease transmitted by the bite of female Anopheles mosqui-
toes. In 2015 alone, the disease led to an estimated 429,000 deaths, with sub-Saharan Africa the most heavily 
affected with 90% of this count. Malaria is most severe in children under five years old, who account for 70% of all 
death1. Features of the life-threatening disease typically consist of metabolic acidosis, severe anaemia, and cere-
bral malaria (CM), with the latter eventuating in approximately 1% of cases worldwide, equal to 1 million people1. 
CM is an often fatal complication of malaria, and the most severe manifestation of the infection, characterised 
by unarousable coma and unconsciousness, often leading to death, or the occurrence of neurological sequelae 
in survivors2. Currently the only treatment options for CM are a combination of immediate intensive care and 
anti-malarial medications3, however resistance is increasingly common, and access to adequate medical care in 
time is not. Non-cerebral malaria (NCM) is another manifestation of severe malaria, resulting in severe anaemia 
and respiratory distress, and can be caused by other strains of Plasmodium, including P. vivax4.
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Of particular pertinence to this study, the pathology of CM is not currently completely understood, though 
several proposed hypotheses have been proposed. The pathogenicity associated with CM is understood to involve 
parasitised red blood cells (PRBCs), endothelial cells, various adhesion molecules and cytokines, platelets, mono-
cytes, and microvesicles released from many different cell types, including several involved in the pathogenesis 
of CM5–8. Within brain microvessels, and in response to the parasite itself, sequestration occurs – that is, the 
cytoadherence of PRBCs, platelets, and monocytes to endothelial and intravascular cells5,6,8. This accumulation 
of cells within the vessels, mediated by adhesion markers such as ICAM-1, VCAM-1, and E-selectin, can trigger 
changes in the function and viability of the cerebral endothelium, destruction of microcirculatory blood flow, 
and hypoxia, leading to blood brain barrier dysfunction and, consequently, several of the clinical manifesta-
tions observed in CM5,7,8. The loss of blood-brain barrier integrity also results in increased permeability, leading 
to increased cerebral oedema, as observed in patients9,10. Parasite infection, as stated previously, induces the 
overproduction of cytokines, such as TNF, lymphotoxin, and IFN-ɣ, and this also results in alterations of the 
cerebral endothelium, upregulation of adhesion molecules, EC apoptosis, and further mediation of cytokine and 
chemokine release11. In recent times, microRNA (miRNA) have also been investigated as to their role in normal 
conditions and deregulation in a number of diseases, including malaria.
miRNA are small, single-stranded non-coding RNA that have been widely demonstrated to be able to regulate 
the expression of at least one third of the human genome and play a critical role in a variety of normal biological 
processes, including cell differentiation, apoptosis, development, and metabolism12. Changes in miRNA expres-
sion have also been identified in a range of diseases, including viral, bacterial, and parasitic infections13–15, includ-
ing malaria. miRNA expression changes in the liver and brain have been studied during malaria using the murine 
model16–18, and within circulating microvesicles19,20, investigating the effect of Plasmodium infection on miRNA 
signatures within these tissues and cells. They found that certain miRNA were down or upregulated, including 
miR-16, miR-27a, miR-150, and miR-451, in response to infection, and that blocking some of these protects 
mice against the development of the infection. The effect of anti-malarial treatment on this expression has also 
been tested, with miRNA expression changes being reversed in some cases21–23. These studies provide supporting 
evidence of the roles that miRNA can play in the pathogenesis of, resistance to, and protective immune response 
against malarial infection.
However, the exact mechanism of action of miRNA during infection, and whether they play either a patho-
genic or a protective role, or a combination of the two, is still not completely understood. Therefore, there is still 
a need for further research in this area. Our study examines the role of miRNA within brain tissue during exper-
imental cerebral or non-cerebral malaria, and in non-infected mice in comparison. We show that, after infection, 
there are changes in specific miRNA in the brain tissue which could provide prospective avenues of research into 
further understanding CM pathogenesis and how to treat or prevent it.
Materials and Methods
Mice. All mice were handled according to approved protocols of the University of Sydney Animal Ethics 
Committee (protocol number 2015/832). 7-10-week-old female CBA mice (Animal Resource Centre, Perth) were 
housed under pathogen-free conditions, fed a commercial rodent pellet diet, and had access to water ad libitum. 
For experimental comparisons, three groups of five mice were included: non-infected (NI), Plasmodium berghei 
ANKA-infected (PbA, CM), and Plasmodium yoelii-infected (Py, NCM). PbA infection of CBA mice leads to fatal 
disease with cerebral pathology during the neurological phase, between day 6 and day 14 post-infection (p.i.)24. 
Mice surviving beyond this point are defined as NCM: i.e. Py infection leads to a fatal but non-cerebral syndrome 
due to hyperparasitaemia and severe anaemia, 14 or more days post infection.
Plasmodium inoculation. All infections were initiated by intraperitoneal injection of 1 × 106 PbA/Py 
PRBCs, as previously described25. Parasitaemia was monitored by counting PRBCs in Diff-Quick-stained thin 
blood smears on day four p.i. and every 1–2 days after this, for the duration of the infection. Mice were assessed 
using a clinical evaluation score, and CM diagnosed if mice presented with ruffled fur, severe motor impairment 
(ataxia, hemiplegia, or paraplegia) or convulsions and was given a score of 3 or 4 as described previously26. This 
diagnosis was then confirmed by histopathology, i.e. presence of leucocyte and PRBC adherence to endothelium, 
haemorrhages, and oedema surrounding vessels. Py-infected mice without any of the symptoms mentioned above 
were classified as NCM.
Brain tissue preparation. At the time of CM for PbA-infected mice, all groups of mice were sacrificed as 
detailed above and brain tissue was collected from infected (CM and NCM), and NI mice. Samples were placed 
immediately in RNAlater (Life Technologies) in a 1:5 volume ratio for complete submersion.
RNA extraction. Total RNA including miRNA was isolated using Ambion mirVanaTM miRNA Isolation Kit 
(Life Technologies). The concentration and purity of total RNA was determined using a NanoDrop-1000 spec-
trophotometer (only RNA samples with A260/A280 and A260/A230 ratios above 2.0 and 1.8, respectively, were 
included into subsequent miRNA profiling studies).
cDNA synthesis and preamplification. 100 ng of total RNA was reverse transcribed using the microRNA 
reverse transcription (RT) reaction kit by following manufacturer’s protocol. After reverse transcription, a 
pre-amplification step was performed as per the manufacturer’s recommendation in order to increase the quan-
tity of desired cDNA before performing PCR, and to significantly increase the ability to detect low abundance 
transcripts. The preamplified product was diluted 40 times by mixing 4 μl of the preamplified product with 156 μl 
of 0.1x Tris-EDTA (TE), pH 8.0.
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OpenArray analysis. After mixing 1:1 with TaqMan OpenArray master mix, pre-amplified samples were 
loaded onto TaqMan OpenArray MicroRNA Panels by using the Accufil system and run on the QuantStudio 12 K 
Flex system (Life Technologies), as per the manufacturer’s instructions. 754 rodent miRNA were amplified in 
each sample, with technical replicates and internal controls. All reactions were performed in duplicate, and each 
technical replicate was analysed on two different OpenArray® Panels. The comparative (ΔΔ) CT method was 
used to quantify relative expression across all miRNA and samples. Resulting Crt values were filtered to exclude 
low-quality reactions with an amplification score below 1.1, following recommendations of Life Technologies 
technicians, where Crt is defined as the PCR cycle number at which the fluorescence meets the threshold in 
the amplification plot. miRNA with a Crt value >29 were considered unamplified. This Crt cut-off was chosen 
since OpenArray® reactions are carried out in small volumes (33 nL); a single molecule is more concentrated in 
a smaller reaction volume and amplifies sooner than it would from regular microplate qPCRs. More concretely, 
single copy numbers will produce, on average, a Crt value of 29 with TaqMan® assays27. Furthermore, for large 
scale miRNA expression profiling studies, it has been demonstrated that global normalisation outperforms the 
normalisation strategy that makes use of small RNA controls28. Consequently, raw Crt values were normalised 
using global normalisation of each pool separately, as per recommendations. After global normalisation, technical 
replicates differing by more than 0.5 standard deviations (SD) were excluded from the analysis, and average ΔCt 
values were estimated for the remaining results. Finally, miRNA which were not amplified in more than 50% of 
samples were considered to be lowly expressed and, therefore, also excluded from the analysis. Using these crite-
ria, 395 miRNA were filtered out leaving 359 miRNA in the final data analysis.
RT-qPCR analysis. The abundance of those miRNAs that showed a differential expression between the NCM 
and the CM group with the OpenArray platform was further validated by TaqMan MicroRNA assays, following 
the manufacturer’s instructions. To this end, five NCM four CM brain samples were included in this analysis. The 
starting RNA concentration was set at 10 ng and each sample was tested in triplicate. U6 and snoRNA-202 were 
identified as suitable endogenous controls and used in this validation step. Real time qPCR was carried out on a 
StepOne Real Time PCR System. Technical replicates for which the SD was >0.5 were removed.
Pathway analysis. DIANA-mirPath v3.0 was used for analysing the combinatorial effect of dysregulated 
miRNAs of interest on target pathways, with a False Discovery Rate (FDR) of 5%. DIANA mirPath is a powerful 
tool to analyse the combinational effects of miRNA on signalling pathways29. This bioinformatics software per-
forms an enrichment analysis of the input datasets by comparing the set of dysregulated miRNA to all available 
biological pathways provided by the Kyoto Encyclopedia of Genes and Genomes (KEGG)30. It should be taken 
into account that, to this end, we used TarBase31 that houses a manually curated collection of experimentally 
proven miRNA targets. Classic miRNA target prediction algorithms were not used due to their intrinsic high false 
positive rates32. The combinatorial effect of co-expressed miRNA in the modulation of a given pathway is taken 
into account by the simultaneous analysis of multiple miRNA. The significantly influenced pathways (p < 0.05) 
were identified.
Statistical analyses. With regards to OpenArray results, differences between experimental groups were 
assessed by Kruskal-Wallis with Dunn post-hoc test, and p-values were adjusted for multiple testing using the 
Benjamini-Hochberg method. The results were calculated using the ΔΔCt method33, and fold change (FC) was 
calculated using the 2−ΔΔCt method, and then data were log2-transformed. Those miRNA with expression dif-
ferences among the three study groups (as determined by Kruskal-Wallis test and corresponding post-hoc tests) 
were included in hierarchical clustering, which was performed using Euclidean distance, complete linkage and 
z-score normalisation. On the other hand, the non-parametric Mann-Whitney U test was used to compare the 
level of expression between the NCM and CM group with qPCR validation results. P-values of <0.05 (two-sided) 
were considered significant. All data were analysed using SPSS Statistics 20 (IBM Corporation), GraphPad Prism 
version 5.02 (GraphPad Software) and RStudio.
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
Results
The changes in miRNA expression in the brains of NI, NCM and CM mice were examined using OpenArray® 
analysis. Unsupervised hierarchical clustering of this set of miRNA separated the samples into two main clusters 
suggesting homogeneity of the miRNA expression profiles within each group. Whilst all CM samples were placed 
in one cluster, the other cluster was constituted by the other two experimental groups, NI and NCM mice (Fig. 1). 
According to this clustering method, the relative expression of dysregulated miRNA in NCM mice was more 
closely related to the NI group than to CM mice. Regarding the set of dysregulated miRNA, two main clusters 
were identified, the first one comprising those miRNA that were upregulated in CM mice whereas those downreg-
ulated were included in the second cluster. The log2 (fold change) was calculated (Table 1), and graphed in Fig. 2 
together with the calculations regarding the significance described above.
We found twelve miRNA to be significantly dysregulated between NI and CM mice: miR-18a-5p, miR-19a-3p, 
miR-20b-5p, miR-21-5p, miR-27a-5p, miR-142-3p, miR-152-3p, miR-155-5p, miR-193a-5p, miR-218-1-3p, miR-
411-5p, and miR-543 (Fig. 2). Two miRNA were differentially expressed between NI mice and NCM mice: miR-
19b-3p and miR-101-3p; and six miRNA between NCM and CM mice: miR-19a-3p, miR-19b-3p, miR-27a-5p, 
miR-142-3p, miR-223-3p, and mmu-miR-540-5p. Three miRNA: miR-19a-3p, miR-27a-5p, and miR-142-3p were 
significantly upregulated in CM mice compared with NI as well as NCM, with NCM being an intermediate in this 
expression comparison.
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Of those miRNA significantly dysregulated in CM vs. NI mice, miR-18a-5p, miR-19a-3p, miR-20b-5p, 
miR-21-5p, miR-27a-5p, miR-142-3p, and miR-155-5p were increased 0.60-2.24 log2-fold, and miR-152-3p, 
miR-193a-5p, miR-218-1-3p, miR-411-5p, and miR-543 were decreased 0.32–0.92 log2-fold. miR-101-3p was 
increased 1.17 log2-fold, and miR-19b-3p was decreased 0.46 log2-fold in NCM vs. NI mice. Finally, in com-
paring NCM vs. CM mice, miR-19a-3p, miR-19b-3p, miR-27a-5p, miR-142-3p, and miR223-3p were increased 
0.44–1.44 log2-fold, and miR-540-5p was decreased 0.87 log2-fold in CM mice.
Our previously identified miRNA of interest – that is, the six miRNA shown to be differentially expressed 
between NCM and CM mouse brain tissue by OpenArray analysis, were analysed for validation by RT-qPCR. 
Significant changes were found in the expression of miR-19a-3p, miR-19b-3p, miR-142-3p, and miR-223-3p, 
as shown in Table 2 and Fig. 3, verifying the differences in miRNA abundance in CM compared with NCM 
found in OpenArray analysis. A significant change of expression was determined for miR-540-5p in NCM com-
pared with CM mice, however this was the opposite change in abundance to that found by OpenArray analy-
sis. No significant difference was found in the abundance of miR-27a-5p between NCM and CM conditions by 
RT-qPCR. Hierarchical clustering was repeated including only this set of six miRNA and qPCR results, and the 
samples belonging to each biological group were clustered separately as observed with OpenArray results (data 
not shown).
Figure 1. Hierarchical clustering of dysregulated miRNA based on Euclidean distance measure and complete 
linkage with Z score normalised gene expression. Each row represents one miRNA and each column represents 
one sample. Red rectangles represent missing values. NI: non-infected; NCM: Plasmodium yoelii-infected mice; 
CM: Plasmodium berghei ANKA-infected mice.
miRNA Kruskal-Wallis test
Log2FC, with Dunn’s + Benjamini-
Hochberg Post-Hoc tests
NI vs. NCM NI vs. CM NCM vs. CM
miR-18a-5p <0.01 1.61
miR-19a-3p <0.05 0.93 0.77
miR-19b-3p <0.05 −0.46 0.44
miR-20b-5p <0.05 1.55
miR-21-5p <0.05 0.60
miR-27a-5p <0.05 1.37 1.09
miR-101-3p <0.05 1.17









Table 1. The list of significantly dysregulated miRNA is shown, with log2 fold change (log2FC) and significance 
calculated for each comparison and each miRNA.
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We then performed pathway analysis on miRNA differentially expressed between CM and NCM, in order to 
identify miRNA with potential roles specifically in the cerebral syndrome. Those miRNA that were upregulated in 
CM mice in comparison with NCM mice as determined by qPCR validation analyses (miR-19a-3p, miR-19b-3p, 
Figure 2. Box plots show miRNA expression levels measured in the three study groups, expressed as 
normalised values using global normalisation. The horizontal line denotes the median value, the box 
encompasses the upper and lower quartiles, whiskers show the range, and the plus symbol denotes the mean. A 
nonparametric Kruskal-Wallis test was carried out. If the Kruskal-Wallis test was significant, post hoc tests were 
carried out, to adjust p-values for multiple testing using the Benjamini-Hochberg method. The results of these 
are denoted in the plot with horizontal bars and asterisks (*P = 0.01–0.05; **P < 0.01). These data represent 
results of duplicate experiments, with 5 animals in each group.
miRNA
Significance of fold change in CM vs. NCM
OpenArray RT-qPCR
Log2 fold change p-value Up- or downregulated Log2 fold change p-value Up- or downregulated
miR-19a-3p 0.77 <0.05 Up 4.86 <0.05 Up
miR-19b-3p 0.44 <0.05 Up 5.24 <0.05 Up
miR-27a-5p 1.09 <0.05 Up 0.1 n.s. —
miR-142-3p 1.19 <0.05 Up 5.98 <0.05 Up
miR-223-3p 1.44 <0.05 Up 4.9 <0.05 Up
miR-540-5p −0.87 <0.05 Down 3.73 <0.05 Up
Table 2. Comparison of results obtained by RT-qPCR and OpenArray analysis.
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miR-142-3p, miR-223-3p and miR-540-5p) were analysed using the DIANA-mirPath v3.0 software, which iden-
tified 16 pathways in mice as significantly enriched (p < 0.05) (Table 2). The pathway relating to endocytosis (3rd 
in the list, p = 2.04E−5), as well as the FoxO (6th, p = 0.0005) and TGF-β signalling (10th, p = 0.007), and adherens 
junctions (13th, p = 0.01) pathways were among the most significantly regulated by our list of miRNA of interest. 
This is particularly interesting as the endocytosis, FoxO signalling and adherens junctions pathways are all intrin-
sically linked to the TGF-β signalling pathway, as they share common elements. Two of these miRNA that were 
more abundant in CM mice (miR-19a-3p and miR-19b-3p) target at least 28 of the genes involved in the FoxO 
signalling pathway, 16 of the genes participating in the TGF-β signalling pathway, and 20 of the genes participat-
ing in the adherens junctions pathway.
When analysing the combinatorial effect of those miRNA upregulated in CM mice (when compared to 
NCM mice) to target pathways in humans, 34 pathways were identified by the software as significantly enriched 
(p < 0.05), including 11 of those also significantly enriched in mice. Of these, the FoxO (4th, p = 5.28E−7) and 
TGF-β signalling (32th, p = 0.023) remained as significantly enriched as identified in mice, although the number 
of experimentally proven targets of these molecules of interest is generally higher in humans than in mice in 
the TarBase database. Specifically when analysing target pathways in humans, three of the miRNA upregulated 
in CM mice (miR-19a-3p, miR-19b-3p and miR-223-3p) target 43 of the genes involved in the FoxO signalling 
pathway, whilst miR-19a-3p and miR-19b-3p regulate the expression of 16 of the genes participating in the TGF-β 
signalling pathway.
Discussion
This study provides the first large-scale analysis of miRNA expression in experimental malaria and reveals that 
Plasmodium infection induces the dysregulation of a specific set of miRNA in the brain, among which are several 
miRNA that are more abundant in CM compared with NCM mice. This group of miRNA likely plays impor-
tant roles in CM, and includes several molecules that are widely associated with inflammatory responses. For 
instance, miR-223 was found to be overexpressed in rheumatoid arthritis34, osteoarthritis35, and inflammatory 
bowel disease36, among others. Furthermore, miR-223 actively participates in infection processes, regulating the 
differentiation of several key players of the innate immune response and therefore, likely plays an important role 
in the early stages of infection37.
Clustering analyses of the OpenArray and qPCR results suggested that those miRNA that showed a differ-
ential expression may represent a miRNA fingerprint of CM, therefore able to distinguish between individuals 
with and without cerebral complications during Plasmodium infections. Nevertheless, the levels of expression of 
this set of miRNA should be further analysed in blood samples from patients with CM and compared to NCM 
patients, in order to confirm their usefulness as biomarkers of CM in humans. This will allow us to characterise 
Figure 3. Boxplots showing the qPCR validation results. The expression levels of miR-19a-3p, miR-19b-3p, 
miR-27a-5p, miR-142-3p, miR-223-3p and miR-540-5p, selected according the OpenArray results outcome, 
were measured by real-time RT-PCR. The horizontal line denotes the median value, the box encompasses the 
upper and lower quartiles, whiskers show the range, and the plus symbol denotes the mean. Mann-Whitney test 
results are denoted in the plot with horizontal bars and asterisks (*P < 0.05).
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the cellular source of these miRNA further, and quantify how the differences in immune cell influx into the brain 
during different disease phases affects miRNA expression, in the future. The utility of miRNA as biomarkers of 
infection has been widely demonstrated in several parasitoses, including schistosomiasis38, filarial infections39, 
and toxoplasmosis40. Among the set of miRNA dysregulated in CM mice, miR-223 has been defined as a potential 
biomarker of infection with Schistosoma japonicum38.
Regarding the relationship between miRNA and malaria, a recent study has demonstrated that intrinsic 
miRNA levels play a significant role in malaria resistance41, proving that miRNA activity may be utilised to 
defend host cells against complex eukaryotic pathogens, not only against viruses as previously demonstrated42. 
LaMonte et al. showed that miR-223, among others, strongly reduces the growth of P. falciparum in erythrocytes 
carrying a variant haemoglobin allele (HbS), which causes sickle cell disease. The authors indicated that the 
antimalarial activity of erythrocyte miRNA requires their entry and subsequent modification of parasite mRNA. 
Consequently, it is possible that the upregulation of at least miR-223 in CM mice may be a targeted anti-parasitic 
immune response, and that miRNA could be used as valuable targets for new therapeutic interventions in malaria 
– a method already being explored in other diseases.
RT-qPCR analysis was employed to validate the expression of six miRNA significantly dysregulated in CM 
conditions, omitting the preamplification step previously employed in the OpenArray analysis. The pream-
plification step, which aims to uniformly increase the levels of miRNAs in the sample, may introduce a bias, 
therefore validation is necessary, as previously demonstrated43–45. Through RT-qPCR analysis, four miRNA were 
validated as more abundant in CM conditions compared with NCM: miR-19a-3p, miR-19b-3p, miR-142-3p and 
miR-223-3p, and these were further investigated by pathway analysis. As a result, we found that some of these 
miRNA molecules are involved in regulating several signalling pathways in CM. Bioinformatics tools indicated 
that hsa-miR-19a-3p, which was upregulated in CM mice compared to NCM mice, can regulate the expression of 
at least 14 out of the 38 genes involved in the TGF-β signalling pathway, as well as many other genes involved in 
other significantly associated pathways.
TGF-β is a superfamily of cytokines, known to regulate cell differentiation, proliferation, apoptosis and pro- 
and anti-inflammatory immune responses46. TGF-β is considered a pivotal regulator of the mammalian response 
to malaria parasite infection, having been described as maintaining “immunological balance” during infection47. 
In our study, we found that two miRNA upregulated in CM compared with NCM mice have been experimentally 
demonstrated to target 16 genes from the TGF-β signalling pathway, which could lead to a miRNA-mediated 
downregulation of their corresponding mRNAs, subsequently altering this pathway, as is consistent with previous 
findings (more detailed information in Fig. S1 and Table S1)48. Similarly, low levels of TGF-β1 have been shown 
to contribute to increased disease severity in mice49 and humans50. Therefore, we suggest that the paramount 
relevance of the TGF-β signalling pathway to Plasmodium infections is, at least partly, due to the action of these 
miRNA.
The most significant relationship was found between miRNA upregulated in CM mice and the endocytosis 
pathway. Endocytosis is a mechanism for cells to remove nutrients, plasma membrane proteins, and lipids from 
the cell surface into the cell interior, by phagocytic or pinocytic methods51. This relationship is of particular inter-
est due to the known role of microvesicles (submicron vesicles released from cell types involved in CM), where 
a significant overproduction is observed in cerebral infection cases only, and not in NI or NCM conditions52. 
Microvesicles have their effect on target tissues through the process of endocytosis into these target cells, therefore 
it is poignant that this pathway should be the most significantly regulated by our miRNA of interest. This link 
supports existing evidence of the role of microvesicles in CM in effecting change within the brain in response to 
infection11. Particularly, recognition of the expression of phosphatidylserine on the surface of microvesicles is 
crucial for phagocytic endocytosis and the subsequent clearance of microvesicles, providing evidence of a poten-
tial protective role played by miRNA in the brain.
The KEGG pathway analysis also showed relationship between miRNA upregulated in CM mice and the FoxO 
signalling pathway. The FoxO family of transcription factors is central to the integration of growth factor sig-
nalling, oxidative stress and inflammation53, by regulating the expression of several antioxidant enzyme genes, 
including superoxide dismutase (sod), and catalase (cat)54. Recently, it was shown that these antioxidant enzyme 
genes were altered at the transcriptional level during Plasmodium infection, indicated by the gradually dimin-
ished expression of superoxide dismutase-1 (sod-1), sod-2, sod-3 and catalase genes55. This family of transcrip-
tion factors also regulates the expression of genes in cellular physiological events including apoptosis and glucose 
metabolism and, considering that impaired glucose production caused by the inhibition of gluconeogenesis is a 
frequently encountered complication in falciparum malaria56, the possible relationship among miRNA, the FoxO 
signalling pathway and glucose concentration should be addressed in the future.
This set of miRNA is involved in the assembly/disassembly of adherens junctions which, together with tight 
junctions, ensure the integrity of vascular endothelial cells forming a barrier that plays a crucial role in the health 
and integrity of the blood-brain barrier (BBB). Disruption of the BBB is a hallmark of immune mediated neu-
rological disorders, including CM57. More concretely, during Plasmodium infection, the endothelium becomes 
activated leading to leakage associated with the disruption of endothelial cell junctional proteins58. However, the 
relationship of miRNA with the disruption of the BBB is almost unknown, but may be linked to the Vascular 
Endothelial cadherin (VE-cad), a component of the adherens junction complex that has emerged as an important 
regulator of endothelial cell-cell adhesion59. It has been shown that, in the presence of high levels of miR-142-3p 
(also upregulated in CM mice in our study), VE-cad (cdh5) levels are suppressed, decreased levels of which are 
known to compromise endothelial cell-cell adhesion thus leading to loss of vascular integrity and remodelling60. 
Furthermore, another component of adherens junctions, β-catenin, has also been found to be targeted in humans 
by miR-142-3p. Strikingly, β-catenin has also been shown to regulate FoxO function under conditions of oxida-
tive stress61, indicating cross-talk between both pathways.
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It is clear that the differences in expression of these miRNA during CM specifically compared with NCM sug-
gests that they, through their regulation of downstream targets, may be vitally involved in the neurological syn-
drome62, although this statement must be further confirmed in future studies by analysing the effect of immune 
cells sequestered to the brain on the miRNA abundance. Collectively, these findings may help to decipher which 
and how miRNA are connected to some of the processes that have been historically implicated in CM patho-
genesis, such as excessive pro-inflammatory cytokine production63,64, loss of endothelial barrier function65,66, 
and endothelial dysregulation67. Nevertheless, how our miRNA of interest are regulating these pathways should 
be analysed more thoroughly in the future due to the complexity of the interactions of these miRNA with their 
numerous mRNAs targets within these pathways.
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